Company / Current Assets per Share
CytomX Therapeutics, Inc. Current Assets per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets per Share
$1.04
FY2025
5-year range
$1.04 / $4.75
FY2021-FY2025
Trend
-22.1%
vs FY2024
Sector context
#192 of 210
Health Care
What the data says
Among 210 Health Care companies, CytomX Therapeutics, Inc. is in the bottom 9% for current assets per share. Current Assets per Share has declined for 5 consecutive years, from $7.12 in FY2020 to $1.04 in FY2025.
Based on SEC 10-K filings.
1.04 in FY2025 with a 5-year CAGR of -31.9%.
Declined from $2.72 to $1.04 over the past 2 years.
Health Care sector context is included.
Current Assets per Share over time
Growth rates
- 3-Year CAGR
- -33.7%
- 5-Year CAGR
- -31.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 210This company $1.04 Sector average $170.65
▼
-99.4% below sector average
Key checks
Key Insights
- CytomX Therapeutics, Inc.'s current assets per share has declined for 5 consecutive years.
- In FY2025, current assets per share decreased 22.1% year-over-year.
- Ranks #192 out of 210 companies in the Health Care sector.
- Peak current assets per share was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current Assets per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.04 | -22.1% |
| FY2024 | $1.34 | -50.7% |
| FY2023 | $2.72 | -24.1% |
| FY2022 | $3.58 | -24.6% |
| FY2021 | $4.75 | -33.3% |
| FY2020 | $7.12 | +6.8% |
| FY2019 | $6.66 | -32.6% |
| FY2018 | $9.88 | -2.2% |
| FY2017 | $10.10 | +95.9% |
| FY2016 | $5.16 | -97.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026